Allero Therapeutics BV logo

Allero Therapeutics BV

NEXT GENERATION IMMUNOTHERAPIES FOR IMMUNE DISORDERS

4 employees · est. 2019 · Rotterdam, The Netherlands

VS
Alumis logo

Alumis

Transforming the lives of patients living with immune-mediated diseases using a precision approach.

249 employees · est. 2021 · South San Francisco, United...

Allero Therapeutics BV is the older company (2019 vs 2021); Alumis is the larger of the two.

Side-by-Side Comparison

Allero Therapeutics BV Alumis
Founded
2019 older 2021
Headquarters
Rotterdam, The Netherlands South San Francisco, United States
Employees
4 249 larger
Industry
Biotechnology, Pharmaceutical Biotechnology, Health Care, Life Sciences
Funding Stage
Grant Series C
Total Funding
$2.57M $529.00M
Funding Rounds
3 3
Services
Not tracked yet Development of targeted therapies, Clinical trial management, Proprietary data analytics for precision medicine, Patient resources and expanded access policy
Target Customers
Not tracked yet Patients with immune-mediated diseases, Healthcare providers, Medical researchers, Investors in biotech and pharmaceutical sectors
Taxonomy
Immunotherapy, Biotech, Therapeutics, Tolerance Induction, Antigen-specific, Autoimmune Diseases, Celiac Diseases, Allergy, COVID-19, ARDS, Food Allergy, Dutch Biotech, SOMIT Technology, Oral Patch Delivery, Immune Disorders Immune-mediated Diseases, Precision Medicine, Targeted Therapies, Drug Development, Autoimmune Diseases, Immunology, Pharmaceuticals, Integrated Therapy Development, Immunosuppression Alternatives, Patient-centric Solutions, Disease-specific Drug Targeting, Therapeutic Innovation, Healthcare Analytics
Website
allerotherapeutics.com alumis.com
Allero Therapeutics BV logo

About Allero Therapeutics BV

Allero Therapeutics is a Dutch biotech company founded in 2016 that is making significant strides in the development of next generation immunotherapies for immune mediated disorders. The company's proprietary SOMIT (Specific Oromucosal Immunotherapy) technology is at the forefront of this innovation...

Alumis logo

About Alumis

Alumis, founded in 2021 and headquartered in the United States, is making strides in the biotechnology, health care, and life sciences industries. The company is committed to transforming the lives of patients with immune-mediated diseases through a precise, targeted approach. By focusing on optimiz...

We will tell you when either one moves

BounceWatch watches Allero Therapeutics BV and Alumis for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Allero Therapeutics BV and Alumis — by email.

Frequently Asked Questions

Allero Therapeutics BV — NEXT GENERATION IMMUNOTHERAPIES FOR IMMUNE DISORDERS. Alumis — Transforming the lives of patients living with immune-mediated diseases using a precision approach.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Allero Therapeutics BV has raised $2.57M while Alumis has raised $529.00M.
Allero Therapeutics BV and Alumis operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Allero Therapeutics BV with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Allero Therapeutics BV on 11 Sep 2024, and Alumis on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy